黄葵胶囊联合还原性谷胱甘肽治疗慢性肾脏病的疗效研究(1)
[摘要] 目的 分析慢性肾脏病采用黄葵胶囊联合还原性谷胱甘肽治疗的临床疗效。 方法 便利选取该院2016年6月—2018年6月收治的100例慢性肾脏病患者为研究对象，随机分为两组，对照组行常规对症治疗，观察组在对照组基础上采用黄葵胶囊联合还原性谷胱甘肽治疗，对比两组治疗前后SCr(血肌酐)、BUN(血尿素氮)、尿 β2-微球蛋白、24 h尿蛋白定量变化情况。结果 观察组治疗后SCr、BUN分别为(102.12±3.28)μmol/L、(7.15±1.08)mmol/L，均低于对照组(t=20.715、18.553，P<0.05);观察组治疗后尿β2-微球蛋白、24 h尿蛋白定量分别为(463.36±4.28)μg/L、(1.52±0.25)g，均少于对照组(t=12.634、11.856，P<0.05)。 结论 慢性肾脏病采用黄葵胶囊联合还原性谷胱甘肽治疗的临床疗效显著，利于改善患者肾功能，延缓病情进展，值得推广。
[关键词] 慢性肾脏病;黄葵胶囊;还原性谷胱甘肽;联合治疗;临床疗效
[中图分类号] R692 [文献标识码] A [文章编号] 1674-0742(2020)04(a)-0097-03
[Abstract] Objective To analyze the clinical effect of Huangkui capsule combined with reduced glutathione in the treatment of chronic kidney disease. Methods From June 2016 to June 2018， 100 patients with chronic kidney disease were randomly divided into two groups. The control group was treated with routine symptomatic treatment. The observation group was convenient treated with Huangkui capsule combined with reduced glutathione on the basis of the control group. The quantitative changes of SCr (serum)， BUN (blood urea nitrogen)， urine β2-microglobulin and 24 h urinary protein were compared between the two groups before and after treatment. Results The SCr， BUN of the observation group after treatment was (102.12±3.28)μmol/L， (7.15±1.08) mmol/L， were lower than those in the control group (t=20.715， 18.553， P<0.05)， and the urinary β2-microglobulin and 24 h urinary protein in the observation group were (463.36±4.28)μg/L and (1.52±0.25)g， respectively， which were lower than those in the control group (t=12.634， 11.856， P<0.05). Conclusion The clinical effect of Huangkui capsule combined with reduced glutathione in the treatment of chronic kidney disease is remarkable， which is beneficial to improve the renal function of the patients and delay the disease. Progress is worth popularizing.
[Key words] Chronic kidney disease; Huangkui capsule; Reduced glutathione; Combined treatment; Clinical efficacy
臨床上，慢性肾脏病是一种以高血压、水肿、蛋白尿以及血尿为表现的临床综合征[1]。若不及时采取有效措施干预，随着病情发展，最终可能进展为慢性肾衰竭[2-3]。研究显示，慢性肾脏病病情进展的重要影响因素为持续性尿蛋白[4]。当患者出现蛋白尿时，会促使肾小管的蛋白质重吸收量明显增多，促使肾小管上皮细胞直接受到损伤，进而导致肾间质纤维化、肾小管功能异常[5-6]。与此同时，蛋白尿作为反映内皮功能的一个重要标志物，会促使肾小球内皮损伤程度进一步加重，促进肾小球硬化，是终末期肾病进展的一个重要危险因素[7-8]。为了改善慢性肾脏病患者预后，延缓病情，需及早采取有效措施对患者进行治疗。该研究在该疾病治疗中联合应用黄葵胶囊与还原性谷胱甘肽，便利选取2016年6月—2018年6月收治的100例慢性肾脏病患者为研究对象，报道如下。
1 资料与方法
1.1 一般资料
从在该院治疗的慢性肾脏病患者中便利选取100例，纳入标准：①患者知情同意;②不存在用药禁忌证。排除标准：①中途退出;②不能严格遵医嘱用药;③合并全身感染性疾病;④存在严重心脑血管并发症。随机将患者分为两组，观察组患者年龄36～83岁，平均年龄(66.39±3.22)岁;共50例，男性30例，女性20例;多囊肾、高血压肾病、糖尿病肾病、慢性肾小球肾炎患者分别有3例、8例、19例、20例。对照组患者年龄35～80岁，平均年龄(65.96±3.26)岁;共50例，男性32例，女性18例;多囊肾、高血压肾病、糖尿病肾病、慢性肾小球肾炎患者分别有2例、9例、20例、19例。对比两组基础资料差异无统计学意义(P>0.05)。具有可比性。, http://www.100md.com(王云霞)
[关键词] 慢性肾脏病;黄葵胶囊;还原性谷胱甘肽;联合治疗;临床疗效
[中图分类号] R692 [文献标识码] A [文章编号] 1674-0742(2020)04(a)-0097-03
[Abstract] Objective To analyze the clinical effect of Huangkui capsule combined with reduced glutathione in the treatment of chronic kidney disease. Methods From June 2016 to June 2018， 100 patients with chronic kidney disease were randomly divided into two groups. The control group was treated with routine symptomatic treatment. The observation group was convenient treated with Huangkui capsule combined with reduced glutathione on the basis of the control group. The quantitative changes of SCr (serum)， BUN (blood urea nitrogen)， urine β2-microglobulin and 24 h urinary protein were compared between the two groups before and after treatment. Results The SCr， BUN of the observation group after treatment was (102.12±3.28)μmol/L， (7.15±1.08) mmol/L， were lower than those in the control group (t=20.715， 18.553， P<0.05)， and the urinary β2-microglobulin and 24 h urinary protein in the observation group were (463.36±4.28)μg/L and (1.52±0.25)g， respectively， which were lower than those in the control group (t=12.634， 11.856， P<0.05). Conclusion The clinical effect of Huangkui capsule combined with reduced glutathione in the treatment of chronic kidney disease is remarkable， which is beneficial to improve the renal function of the patients and delay the disease. Progress is worth popularizing.
[Key words] Chronic kidney disease; Huangkui capsule; Reduced glutathione; Combined treatment; Clinical efficacy
臨床上，慢性肾脏病是一种以高血压、水肿、蛋白尿以及血尿为表现的临床综合征[1]。若不及时采取有效措施干预，随着病情发展，最终可能进展为慢性肾衰竭[2-3]。研究显示，慢性肾脏病病情进展的重要影响因素为持续性尿蛋白[4]。当患者出现蛋白尿时，会促使肾小管的蛋白质重吸收量明显增多，促使肾小管上皮细胞直接受到损伤，进而导致肾间质纤维化、肾小管功能异常[5-6]。与此同时，蛋白尿作为反映内皮功能的一个重要标志物，会促使肾小球内皮损伤程度进一步加重，促进肾小球硬化，是终末期肾病进展的一个重要危险因素[7-8]。为了改善慢性肾脏病患者预后，延缓病情，需及早采取有效措施对患者进行治疗。该研究在该疾病治疗中联合应用黄葵胶囊与还原性谷胱甘肽，便利选取2016年6月—2018年6月收治的100例慢性肾脏病患者为研究对象，报道如下。
1 资料与方法
1.1 一般资料
从在该院治疗的慢性肾脏病患者中便利选取100例，纳入标准：①患者知情同意;②不存在用药禁忌证。排除标准：①中途退出;②不能严格遵医嘱用药;③合并全身感染性疾病;④存在严重心脑血管并发症。随机将患者分为两组，观察组患者年龄36～83岁，平均年龄(66.39±3.22)岁;共50例，男性30例，女性20例;多囊肾、高血压肾病、糖尿病肾病、慢性肾小球肾炎患者分别有3例、8例、19例、20例。对照组患者年龄35～80岁，平均年龄(65.96±3.26)岁;共50例，男性32例，女性18例;多囊肾、高血压肾病、糖尿病肾病、慢性肾小球肾炎患者分别有2例、9例、20例、19例。对比两组基础资料差异无统计学意义(P>0.05)。具有可比性。, http://www.100md.com(王云霞)
参见：首页 > 医疗版 > 疾病专题 > 泌尿外科 > 肾脏 > 肾脏知识